Treatment for Ventricular Function

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Ventricular Function
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will compare the accuracy of two methods for measuring RV volumes, with CMR as the gold standard.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 0 days

0 days
Mean absolute %error in RVEDV/RVESV/RVEF (subcostal window)
Mean absolute %error in end diastolic volume measurements
Mean absolute %error in right ventricular end systolic volume (RVESV) / right ventricular ejection fraction (RVEF)

Trial Safety

Trial Design

0 Treatment Group

50 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 0 days

Who is running the clinical trial?

Boston Children's HospitalLead Sponsor
710 Previous Clinical Trials
5,324,183 Total Patients Enrolled
David M Harrild, MD, PhDPrincipal InvestigatorBoston Children's Hospital

Eligibility Criteria

Age < 65 · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 20th, 2021

Last Reviewed: October 26th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References